February 04, 2015
A Florida federal judge signed off Wednesday on a $1.25 million settlement that ends a class action brought by stockholders of Accentia Biopharmaceuticals Inc. and a subsidiary accusing the companies of lying to investors about the performance of a non-Hodgkin's lymphoma treatment vaccine in development.
September 05, 2014
An Accentia Biopharmaceuticals Inc. subsidiary agreed Friday to pay $1.25 million to settle a putative securities class action in Florida federal court accusing the company of lying to investors about the performance of a non-Hodgkin's lymphoma treatment vaccine in development that artificially inflated both companies' stock prices.
July 29, 2013
The directors of Accentia Biopharmaceuticals Inc. subsidiary Biovest International Inc. lied to investors about the performance of a non-Hodgkin's lymphoma treatment vaccine that Biovest was developing, artificially inflating the companies' stock prices, according to a securities class action filed Friday in Florida federal court.